XML 90 R78.htm IDEA: XBRL DOCUMENT v3.21.4
SUBSEQUENT EVENTS (Details)
12 Months Ended
Nov. 05, 2021
USD ($)
$ / shares
shares
Nov. 04, 2021
USD ($)
item
shares
Oct. 04, 2021
USD ($)
shares
Sep. 30, 2021
USD ($)
shares
Sep. 30, 2020
USD ($)
shares
Nov. 03, 2021
USD ($)
shares
SUBSEQUENT EVENTS            
Consideration in cash       $ 41,590,000 $ 3,931,000  
Common Stock, Shares Authorized | shares       19,000,000 19,000,000  
2018 Equity Incentive Plan            
SUBSEQUENT EVENTS            
Number of shares added under amended and restated plan | shares   1,500,000   700,000    
Envigo            
SUBSEQUENT EVENTS            
Transaction costs       $ 4,124,000    
Subsequent events            
SUBSEQUENT EVENTS            
Common and preferred shares authorized   $ 75,000,000       $ 20,000,000
Common Stock, Shares Authorized | shares   74,000,000       19,000,000
Preferred Stock, Shares Authorized | shares   1,000,000       1,000,000
Number of shares added under amended and restated plan | shares   1,500,000        
Subsequent events | Revolving Facility            
SUBSEQUENT EVENTS            
Principal amount of revolving loan facility $ 15,000,000          
Maximum amount of line of credit 25,000,000          
Subsequent events | Plato BioPharma Inc            
SUBSEQUENT EVENTS            
Transaction consideration in business acquisition     $ 15,000,000      
Consideration in cash     $ 10,000,000      
Shares issued | shares     57,587      
Common shares value     $ 2,000,000      
Weighted average closing price of shares     20 days      
Liabilities incurred     $ 3,000,000      
Subsequent events | Envigo            
SUBSEQUENT EVENTS            
Consideration in cash $ 205,200,000          
Shares issued | shares 8,245,918          
Adjustments for net working capital $ 13,000,000          
Shares issuable upon exercise of stock options | shares 790,620          
Exercised weighted-average exercise price (in dollars per share) | $ / shares $ 44.80          
Stock issued in acquisition (In shares) | shares 8,245,918          
Stock price on acquisition date (per share) | $ / shares $ 53.31          
Value of shares issued upon exercise of stock options included in consideration transferred $ 19,500,000          
Number of board members | item   7        
Subsequent events | Term Loan            
SUBSEQUENT EVENTS            
Principal amount 165,000,000          
Subsequent events | Delayed Draw Term Loan            
SUBSEQUENT EVENTS            
Principal amount $ 35,000,000          
Maximum term for drawing loan facility 18 months